Introduction
Breast cancer is the most frequent malignancy in women worldwide with an estimated 1.4 million new cases in 2010 (1) . Breast-conserving therapy (BCT), consisting of breast-conserving surgery (BCS) followed by radiation therapy, has become the standard treatment for T1-T2 breast tumours and is generally regarded as sufficient for this subset of patients (2) . Unfortunately, a majority of studies on the surgical margin status after BCS have shown that positive margins are detected in 20 to 40% of patients, necessitating additional surgical intervention or radiotherapy (3) .
Two major points for improving outcome after BCS involve i) a more reliable intraoperative tumour localization and ii) improved real-time feedback on the presence of possible residual disease during or after excision of the tumour (4) .
Intraoperative application of an optical imaging technique known as near-infrared fluorescence (NIRF) imaging may improve the clinical outcome of BCS (3;5) .
Near-infrared fluorescence imaging
In recent years, significant progress has been made in the development of optical imaging systems and fluorophores for clinical applications (6;7). Several animal (5;8-10) and clinical (11) (12) (13) (14) (15) studies have shown the potential clinical use of NIRF imaging to improve the therapeutic outcome of surgery. Compared to light in the visible spectral range (400-650 nm), application of near-infrared (NIR) light minimizes absorption by physiologically abundant molecules such as hemoglobin and lipids, which increases penetration depth (16;17) . Additionally, autofluorescence (the intrinsic fluorescence signal present in all living cells due to various normal metabolites and tissue constituents) is strongly reduced in the NIR spectral range.
Taken together, these aspects of NIR light make it particularly suitable for use in M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 intraoperative optical imaging applications. However, clinical application of NIRF imaging in BCS is currently limited to the non-specific intraoperative detection of the sentinel lymph node (11;12;14;18-20) .
Tumour-targeted near-infrared fluorophores
With the introduction of clinical grade tumour-targeted NIR fluorophores, NIRF imaging may be extended towards the intraoperative detection of the primary tumour (10) . Several target molecules have been indentified for breast cancer that may be of value for such an approach, including Her2/neu receptor (9;21;22) , vascular endothelial growth factor (VEGF) receptor (23;24), endothelial growth factor (EGF) receptor (25) and folate receptor-α (26).
In tumour-targeted NIRF imaging, a tumour-targeted NIR fluorophore is administered several hours or days prior to the imaging procedure. Subsequently, an external laser is used to irradiate the breast with light in the NIR spectral range (650-900 nm) (17) .
Upon excitation, the fluorophore will release photons of a higher NIR wavelength.
Because NIR light is invisible to the naked eye, a dedicated optical imaging system is necessary to capture the NIR signal from the surgical field and digitally convert it to a visible image. Recently, we and our co-workers developed a multispectral NIRF intraoperative camera system that is suitable for intraoperative use with NIR fluorophores (27) .
Simulation of NIRF-guided breast-conserving surgery
In the current preclinical study, we evaluated intraoperative NIRF imaging applications in a simulated clinical setting as a step-up toward NIRF-guided BCS. To this end, we used tissue-simulating gelatin-based breast phantoms that mimic the 
Material and Methods

Assessment of ICG fluorescence self-quenching in agarose
Because increasing concentrations of ICG may not correspond to an increased fluorescence signal due to self-quenching of ICG, different concentrations of ICG in agarose were evaluated for fluorescence activity (29;30) . Briefly, an ICG stock solution was serially diluted in 10 ml sterile water (ranging from 0.5 uM to 350 uM ICG), after which 2% agarose was added. The mixture was then heated to 70°C and stirred until the agarose was completely dissolved. After solidification of the agarose mixture for 15 min at 4°C, fluorescence reflectance imaging (FRI) was performed to determine maximum photon counts/sec (settings: exposure time: 1000 ms, excitation: 780 nm, emission: 820 nm). 
Assessment maximal penetration depth of ICG fluorescence
Tissue-Simulating Breast Phantoms
Composition of the tissue-simulating gelatin-based breast phantoms was aimed at obtaining uniform optical properties that closely match the optical characteristics of normal breast tissue, as described in detail before (29) . Additionally, the breast phantoms mimic the elastic properties of human tissue (31) .
Briefly, 10% gelatin 250 (Natural Spices, Watergang, the Netherlands) was dissolved Tumour-like fluorescent inclusions of different size (range: 0.5 cm to 2.0 cm) and shape (prolate sphere, sphere and irregular shape, Figure 1A 
Tumour-like NIR fluorescent agarose inclusions
Simulation of intraoperative NIRF imaging
Breast phantoms with tumour-like NIR fluorescent agarose inclusions were used to simulate and evaluate the potential of NIRF imaging applications in BCS (Figure 1 
Results
ICG fluorescence self-quenching in agarose
To determine the optimal ICG concentration in agarose, a serial range of increasing ICG concentrations was analyzed for fluorescence characteristics. The optimal fluorescence signal was observed at a concentration of approximately 10 µM ICG ( Figure 4) . These results are comparable to self-quenching characteristics of ICG as previously determined in gelatin (29) .
Maximal penetration depth of ICG fluorescence
The maximal tissue penetration depth of a detectable fluorescent ICG inclusion was reached at a depth of 21 mm ( Figure 2C and supplemental video 2) . 
Simulation of intraoperative NIRF imaging
Discussion
Tissue-like phantoms and tumour-like inclusions
The composition of the breast phantoms was based on data published by De Grand et al, who developed and validated phantoms to mimic the basic optical characteristics (absorption and scattering coefficients) of breast tissue (29) . The absorption of photons by both cellular organelles and blood was simulated by hemoglobin, which gives the phantoms a deep red colour (32;33) . Additionally, Intralipid ® was added to mimic scattering properties of breast tissue (28) . This difference in penetration depth is due to the application of different imaging strategies which are largely incompatible with surgery, e.g. trans-illumination and the need for light conduction liquid media.
Non-specific versus tumour-targeted fluorophores
Several possibilities exist for delivering fluorophores to the tumour. One possibility would be to inject a non-specific fluorophore (e.g. ICG) into the tumour under stereotactic or ultrasonographic guidance (35) . However, there are some significant drawbacks to this approach. First, the injection of the nonspecific fluorophore into the tumour is a critical step in the procedure and has to be very accurate to minimize false-negative and false-positive results. Additionally, spillage/leakage of fluorophore M A N U S C R I P T
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16 within the mammary gland during the procedure will decrease accuracy of both localization of the tumour and macroscopic margin assessment. Therefore, we believe NIRF-guided surgery should ideally be combined with tumour-targeted fluorophores, which provide molecularly-specific detection of cancer cells. In these agents, the NIR fluorophore has been conjugated to a specific targeting ligand or monoclonal antibody. This allows for tumour-specific binding of the fluorophore, increasing SN ratios and minimizing spillage of the fluorophore during the surgical procedure (3;10). Several studies have shown the feasibility of using tumour-targeted fluorophores in vivo to image tumours intraoperatively, including the use of tumourtargeted ICG-conjugated agents (5;9;22;25;26;36;37) . However, there are some significant drawbacks, including the heterogeneity of (breast) tumours which should be solved before applying tumour-targeted NIRF imaging in the clinic. In BCS, the preoperative biopsy taken prior to surgery could provide important information on molecular targets for NIRF imaging. As this biopsy is considered standard practice, it will not require an additional invasive procedure, while offering the possibility to determine the expression of different kinds of molecular targets present on the breast cancer cells by immunohistochemical analysis. The surgeon could then look for NIRF agents suited for each individual tumour, offering a more patient-tailored approach. 
